Print Page     Close Window     

SEC Filings

8-K
SERES THERAPEUTICS, INC. filed this Form 8-K on 08/02/2018
Entire Document
 


SERES THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(unaudited, in thousands, except share and per share data)

 

     Three Months Ended June 30,     Six Months Ended June 30,  
     2018     2017     2018     2017  

Revenue:

        

Collaboration revenue - related party

   $ 4,271     $ 3,014     $ 8,037     $ 6,029  

Grant revenue

     341       —         546       —    
  

 

 

   

 

 

   

 

 

   

 

 

 

Total revenue

     4,612       3,014       8,583       6,029  

Operating expenses:

        

Research and development expenses

     24,053       23,060       47,513       43,203  

General and administrative expenses

     8,695       8,370       17,472       17,132  
  

 

 

   

 

 

   

 

 

   

 

 

 

Total operating expenses

     32,748       31,430       64,985       60,335  
  

 

 

   

 

 

   

 

 

   

 

 

 

Loss from operations

     (28,136     (28,416     (56,402     (54,306
  

 

 

   

 

 

   

 

 

   

 

 

 

Other income (expense):

        

Interest income

     349       615       696       1,390  

Other income (expense)

     —         (217     —         (576
  

 

 

   

 

 

   

 

 

   

 

 

 

Total other income, net

     349       398       696       814  
  

 

 

   

 

 

   

 

 

   

 

 

 

Net loss

   $ (27,787   $ (28,018   $ (55,706   $ (53,492
  

 

 

   

 

 

   

 

 

   

 

 

 

Net loss per share attributable to common stockholders, basic and diluted

   $ (0.68   $ (0.69   $ (1.37   $ (1.32
  

 

 

   

 

 

   

 

 

   

 

 

 

Weighted average common shares outstanding, basic and diluted

     40,661,464       40,394,605       40,645,040       40,381,643  
  

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive (loss) income:

        

Unrealized (loss) gain on investments, net of tax of $0

     77     $ (25   $ 117     $ (27
  

 

 

   

 

 

   

 

 

   

 

 

 

Total other comprehensive (loss) income

     77       (25     117       (27
  

 

 

   

 

 

   

 

 

   

 

 

 

Comprehensive loss

   $ (27,710   $ (28,043   $ (55,589   $ (53,519
  

 

 

   

 

 

   

 

 

   

 

 

 

IR or PR Contact:

Carlo Tanzi, Ph.D., Seres Therapeutics, 617-203-3467

Vice President, Investor Relations and Corporate Communications

ctanzi@serestherapeutics.com

###


© Seres Therapeutics. All Rights Reserved.